RespireRx Pharmaceuticals Inc (RSPI): I wonder what will become of this Org-24...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	87
Posts	33938
Boards Moderated	87
Alias Born	03/22/2005

gfp927z

Re: None

Monday, 03/12/2007 7:24:37 PM

Monday, March 12, 2007 7:24:37 PM

I wonder what will become of this Org-24448 study once Schering owns Org-24448 (farampator)? The "ATP Group" list it as an upcoming study, so I don't know if it was ever started. It looks to be completely different from the NIMH/TURNS trial, though both are combination therapy Schizo trials. One would assume that Organon must have given their consent for this trial, though perhaps that was given during the period when it looked like the TURNS trial wasn't going to happen -

http://www.pacificneuropsych.com/espanol/research.html

>>> ATP Clinical Research, Inc.
3151 Airway Ave
Bldg T, Ste 3
Costa Mesa, CA
Tel: 714-277-4472
Fax: 714-545-5748

Upcoming Studies

A multi-center, randomized, double-blind, fixed-dose, efficacy and safety trial of farampator (250 and 500 mg b.i.d) vs. placebo as augmentation therapy in schizophrenia subjects currently receiving risperidoe (2 or 3 mg b.i.d.) <<<

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent RSPI News

Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 12:45:11 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 12:30:23 PM
Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 08:01:32 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 01:03:20 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM